Multiple circumscribed subcutaneous lipomas associated with use of human immunodeficiency virus protease inhibitors? [13]

British Journal of Dermatology

Volumn 143, Issue 5, 2000, Pages 1113-1114

  Bornhovd, E ^a   Sakrauski, A K ^a   Bruhl, H ^a   Walli, R ^a   Plewig, G ^a   Rocken, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LETTER; LIPID METABOLISM; LIPODYSTROPHY; LIPOMA; LIPOMATOSIS; MALE; PRIORITY JOURNAL; VIRUS LOAD;

DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV PROTEASE INHIBITORS; HUMANS; LIPOMATOSIS; MALE; MIDDLE AGED;

EID: 0033749237     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03871.x     Document Type: Letter

References (7)

1. Benign symmetric lipomatosis associated with protease inhibitors
2. Abnormal fat accumulation in patients with HIV-1 infection
3. Visceral abdominal-fat accumulation associated with the use of indinavir
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
6. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients
7. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy